These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24447197)

  • 1. Designing inhibitors of anthrax toxin.
    Nestorovich EM; Bezrukov SM
    Expert Opin Drug Discov; 2014 Mar; 9(3):299-318. PubMed ID: 24447197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?
    Antoniu SA
    Expert Opin Investig Drugs; 2010 Jul; 19(7):909-11. PubMed ID: 20450444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obiltoxaximab: First Global Approval.
    Greig SL
    Drugs; 2016 May; 76(7):823-30. PubMed ID: 27085536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of the Efficacy of FDA-Approved
    Couse Z; Cui X; Li Y; Moayeri M; Leppla S; Eichacker PQ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33450877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative pre-approved and novel therapies for the treatment of anthrax.
    Head BM; Rubinstein E; Meyers AF
    BMC Infect Dis; 2016 Nov; 16(1):621. PubMed ID: 27809794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Therapeutically Active Molecules against Anthrax through Structure and Ligand based Drug Design.
    Nandi S; Saxena M; Saxena AK
    Curr Top Med Chem; 2018; 18(27):2294-2312. PubMed ID: 30582475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of anthrax lethal factor metalloproteinase inhibitors.
    Turk BE
    Curr Pharm Biotechnol; 2008 Feb; 9(1):24-33. PubMed ID: 18289054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.
    Beierlein JM; Anderson AC
    Curr Med Chem; 2011; 18(33):5083-94. PubMed ID: 22050756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raxibacumab.
    Mazumdar S
    MAbs; 2009; 1(6):531-8. PubMed ID: 20068396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine.
    McComb RC; Martchenko M
    Vaccine; 2016 Jan; 34(1):13-9. PubMed ID: 26611201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does anthrax antitoxin therapy have a role in the treatment of inhalational anthrax?
    Vietri NJ
    Curr Opin Infect Dis; 2018 Jun; 31(3):257-262. PubMed ID: 29570493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors.
    Cai C; Che J; Xu L; Guo Q; Kong Y; Fu L; Xu J; Cheng Y; Chen W
    PLoS One; 2011; 6(6):e20646. PubMed ID: 21674060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.
    Zai X; Zhang J; Liu J; Liu J; Li L; Yin Y; Fu L; Xu J; Chen W
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26927174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.
    Ohanjanian L; Remy KE; Li Y; Cui X; Eichacker PQ
    Expert Opin Investig Drugs; 2015; 24(7):851-65. PubMed ID: 25920540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthrax Toxins in Context of Bacillus anthracis Spores and Spore Germination.
    Cote CK; Welkos SL
    Toxins (Basel); 2015 Aug; 7(8):3167-78. PubMed ID: 26287244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge.
    Mett V; Chichester JA; Stewart ML; Musiychuk K; Bi H; Reifsnyder CJ; Hull AK; Albrecht MT; Goldman S; Baillie LW; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():183-90. PubMed ID: 21270531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.
    Moayeri M; Robinson TM; Leppla SH; Karginov VA
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2239-41. PubMed ID: 18378717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
    Loving CL; Khurana T; Osorio M; Lee GM; Kelly VK; Stibitz S; Merkel TJ
    Infect Immun; 2009 Jan; 77(1):255-65. PubMed ID: 18955474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.
    Slay RM; Cook R; Hendricks K; Boucher D; Merchlinsky M
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S441-S450. PubMed ID: 36251555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.